OPKO Health, Inc. $OPK Shares Acquired by Invesco Ltd.

Invesco Ltd. lifted its holdings in shares of OPKO Health, Inc. (NASDAQ:OPK) by 4.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,623,600 shares of the biotechnology company’s stock after buying an additional 69,111 shares during the period. Invesco Ltd. owned approximately 0.20% of OPKO Health worth $2,695,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Oak Thistle LLC bought a new position in shares of OPKO Health in the first quarter valued at $26,000. Cerity Partners LLC bought a new position in shares of OPKO Health in the first quarter valued at $36,000. Pallas Capital Advisors LLC bought a new position in shares of OPKO Health in the first quarter valued at $43,000. Wealth Enhancement Advisory Services LLC increased its holdings in shares of OPKO Health by 75.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 12,417 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV increased its holdings in shares of OPKO Health by 105.6% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 43,167 shares of the biotechnology company’s stock valued at $63,000 after buying an additional 22,167 shares in the last quarter. Institutional investors own 64.63% of the company’s stock.

OPKO Health Stock Down 2.8%

NASDAQ OPK opened at $1.38 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.02 and a current ratio of 3.41. The firm has a 50-day simple moving average of $1.34 and a 200 day simple moving average of $1.45. OPKO Health, Inc. has a twelve month low of $1.11 and a twelve month high of $2.04. The stock has a market cap of $1.10 billion, a PE ratio of -5.52 and a beta of 1.19.

OPKO Health (NASDAQ:OPK) last released its earnings results on Thursday, July 31st. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.07). OPKO Health had a negative net margin of 26.68% and a negative return on equity of 13.17%. The company had revenue of $156.80 million during the quarter, compared to the consensus estimate of $165.74 million. During the same quarter in the previous year, the business posted ($0.01) EPS. The firm’s quarterly revenue was down 13.9% on a year-over-year basis. On average, research analysts forecast that OPKO Health, Inc. will post -0.25 EPS for the current year.

Insider Buying and Selling at OPKO Health

In related news, CEO Phillip Md Et Al Frost bought 675,000 shares of OPKO Health stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average price of $1.32 per share, for a total transaction of $891,000.00. Following the completion of the purchase, the chief executive officer owned 214,676,448 shares in the company, valued at approximately $283,372,911.36. This represents a 0.32% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 49.69% of the company’s stock.

Analysts Set New Price Targets

OPK has been the topic of several recent analyst reports. LADENBURG THALM/SH SH raised shares of OPKO Health to a “strong-buy” rating in a research note on Tuesday, July 8th. Zacks Research raised shares of OPKO Health from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 14th. Finally, Wall Street Zen downgraded shares of OPKO Health from a “hold” rating to a “sell” rating in a research report on Monday, May 5th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, OPKO Health has a consensus rating of “Moderate Buy” and a consensus target price of $2.75.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.